Skip to main content
4BASEBIO PLC logo

4BASEBIO PLC — Investor Relations & Filings

Ticker · 4BB ISIN · GB00BMCLYF79 LEI · 213800E2DX9EAIUNCB30 IL Manufacturing
Open in API
Filings indexed 104 across all filing types
Latest filing 2026-06-16 Investor Presentation
Country GB United Kingdom
Listing IL 4BB

About 4BASEBIO PLC

https://www.4basebio.com/

4BASEBIO PLC is a biotechnology company specializing in the design and manufacturing of synthetic DNA for next-generation therapeutics and vaccines. The company provides high-purity, Good Manufacturing Practice (GMP) grade nucleic acid products, including its proprietary opDNA®, as a plasmid-free alternative to traditional methods. Its technology is engineered to accelerate development timelines, enhance safety, and improve manufacturing scalability for applications in genetic medicine, including mRNA vaccines, viral vector-based gene therapies, and gene editing. 4basebio's solutions aim to eliminate production bottlenecks and de-risk manufacturing for partners in the pharmaceutical and biotechnology sectors.

Recent filings

Filing Released Lang Actions
4basebio Plc - Notice of Investor Presentation
Investor Presentation Classification · 95% confidence The document is a notice announcing a live investor presentation by 4basebio PLC scheduled on a future date (29 June 2026). It explicitly states no new material information will be disclosed during the event, and provides details on how investors can participate or submit questions. The document is short (2669 characters) and serves to inform the market about the upcoming presentation rather than containing financial data or detailed financial reports. This matches the description of an Investor Presentation (IP) notice rather than the presentation content itself, but since the notice is the main document and no detailed presentation materials are included, it fits best as an Investor Presentation announcement. However, given the document content is essentially an announcement of the event rather than the presentation materials, it might be tempting to classify as Report Publication Announcement (RPA), but the event is not a release of a report. Therefore, Investor Presentation (IP) is the correct classification here.
2026-06-16 English
4basebio Plc - 4basebio Appoints Dr. Jeff Coller to Strategic Advisory Board
Board/Management Information Classification · 95% confidence The document is a press release announcing the appointment of Dr. Jeff Coller to the Strategic Advisory Board of 4basebio PLC. It contains no financial data, regulatory form references, or report content. The announcement focuses on management advisory board appointment and does not relate to audit, financial results, voting results, or other regulatory filings. Hence, it fits best under Board/Management Information (MANG).
2026-06-15 English
4basebio Plc - Notice of Annual General Meeting
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice to shareholders of the upcoming Annual General Meeting, including the notice of meeting, explanatory notes on resolutions, proxy voting instructions, form of proxy, and related party transaction disclosure. It is intended to solicit shareholder votes and provide full information ahead of the AGM—not the AGM materials themselves or the final vote results. This matches the definition of a Proxy Solicitation & Information Statement (PSI).
2026-06-05 English
4basebio Plc - Director Dealing
Director's Dealing Classification · 85% confidence The document is an announcement that Dr. Amy Walker, a director and CEO, has acquired ordinary shares and includes the required Notification of Dealing table and details. This matches the definition of a Director’s Dealing (insider share transaction) rather than a company share buyback or other filing. Therefore, it should be classified as DIRS.
2026-05-22 English
4basebio Plc - Final Results and Notice of AGM
Earnings Release Classification · 92% confidence The document is a press‐style announcement dated 20 May 2026, titled “Final Results and Notice of AGM,” presenting audited financial highlights (revenue, loss, cash), operational highlights, post‐period events, and CEO/Chair commentary for the year ended 31 December 2025. It is an initial summary release of annual results, not the full Annual Report (which is stated to follow), and is formatted as a results announcement rather than a complete 10-K/AR. This aligns with an Earnings Release (ER) under the taxonomy. Therefore, it is classified as ER. FY 2025
2026-05-20 English
4basebio Plc - 4basebio Signs Clinical Supply Agreement to Support Phase II Clinical Trial
Regulatory Filings Classification · 85% confidence The document is a short press release announcing that 4basebio PLC has signed a Clinical Supply Agreement to support a Phase II clinical trial. It contains inside information notice under EU market abuse rules. There is no financial statement detail, dividends, or management changes. It does not present a formal report (none of the quarterly/annual report formats) but is a regulatory news announcement. This fits the “Regulatory Filings (RNS)” category.
2026-05-20 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.